Report Library
All Reports
Non-Small Cell Lung Cancer Second Line or Greater Therapy Trials, Phase III
August 27, 2015
Trying to predict the trial completion date for all competitors in your space can be costly and time consuming. This Citeline Trialscape
analyzes all ongoing Phase III and pivotal Phase II second line non-small cell lung cancer trials and maps the full competitive landscape,
helping you determine who will finish first.
How will this give me an advantage?
Trialscape is a powerful visual analysis tool derived from comprehensive clinical trials intelligence from Citeline. All trials are mapped along an interactive timeline and hyperlink to the full trial record in a dynamic Excel format. The result is a unique and strategic view of the competitive landscape. For further details of Trialscape please click here for details.
I’m interested, how do I get this?
How will this give me an advantage?
- Quickly determine the future therapeutic landscape in a snapshot using the interactive trial map
- Evaluate the competition and how you measure up by accessing full trial details on patient population, locations, endpoints, treatment plan, design and results
- Guide strategic decision making in drug development, clinical operations and marketing - using clinical trial data you can trust and a time-saving tool that’s easy to use
- Realize commercial objectives by identifying potential targets for in-licensing and partnering
Trialscape is a powerful visual analysis tool derived from comprehensive clinical trials intelligence from Citeline. All trials are mapped along an interactive timeline and hyperlink to the full trial record in a dynamic Excel format. The result is a unique and strategic view of the competitive landscape. For further details of Trialscape please click here for details.
I’m interested, how do I get this?
- Purchase now using your credit card for immediate access
- Contact us and we can answer any questions you may have. We can also offer bundle prices for multiple Trialscape products. If your interest is in other therapeutic areas not on offer, our analysts can work with you to create a custom deliverable. Please contact analytics@citeline.com for more information.
- Amgen
- Ariad
- AstraZeneca
- BeyondSpring Pharmaceuticals
- Boehringer Ingelheim
- Clovis Oncology
- Daiichi Sankyo
- Eli Lilly
- Jiangsu Hengrui Medicine Co.
- KAEL-GemVax
- Merck & Co.
- Merck KGaA
- National Institutes of Health
- NewLink Genetics
- Novartis
- OncoGenex Pharmaceuticals
- Peregrine Pharmaceuticals
- Pfizer
- Roche
- Southwest Oncology Group
- Synta Pharmaceuticals
- Teva
- Threshold Pharmaceuticals
| Disease Group Covered: | Oncology |
| Indications Covered: | Castleman's Disease |
Additional Resources:
- Citeline Trialscapes: ADC's in Oncology, Phase III
- Citeline Trialscapes: Biosimilars in Oncology - Hematological Cancers, All Phases
- Citeline Trialscapes: Biosimilars in Oncology - Solid Tumors, All Phases
- Citeline Trialscapes: Breast Cancer First Line Therapies, Phase III
- Citeline Trialscapes: Breast Cancer Second Line or Greater Therapies, Phase III
- Citeline Trialscapes: Hormone Refractory Prostate Cancer Therapies, Phase III
- Citeline Trialscapes: Non-Small Cell Lung Cancer First Line Therapies, Phase III
- Citeline Trialscapes: Pancreatic Cancer Therapies, Phase III